It's complicated: The relationship of non-narcotic medications and postoperative opioid use in radical cystectomy patients

Samuel J Ivan; Emily H Roebuck; Alexander L Sinks; Myra M Robinson; Peter E Clark; Kris E Gaston; Justin T Matulay; Stephen B Riggs

doi:10.1016/j.urolonc.2024.03.007

It's complicated: The relationship of non-narcotic medications and postoperative opioid use in radical cystectomy patients

Urol Oncol. 2024 May 11:S1078-1439(24)00363-6. doi: 10.1016/j.urolonc.2024.03.007. Online ahead of print.

Authors

Samuel J Ivan¹, Emily H Roebuck¹, Alexander L Sinks¹, Myra M Robinson², Peter E Clark¹, Kris E Gaston³, Justin T Matulay¹, Stephen B Riggs⁴

Affiliations

¹ Department of Urology, Carolinas Medical Center, Atrium Health, Levine Cancer Institute, Charlotte, NC.
² Department of Cancer Biostatistics, Carolinas Medical Center, Atrium Health, Levine Cancer Institute, Charlotte, NC.
³ Department of Urology, University of Texas Southwestern, Dallas, TX.
⁴ Department of Urology, Carolinas Medical Center, Atrium Health, Levine Cancer Institute, Charlotte, NC. Electronic address: stephen.riggs@atriumhealth.org.

PMID: 38735799
DOI: 10.1016/j.urolonc.2024.03.007

Abstract

Introduction: The effect of individual non-narcotic analgesics in cystectomy enhanced recovery after surgery (ERAS) is unknown. Additionally, many non-narcotic medications are associated with side effects pertinent to the cystectomy population. To better understand the actual use and utility of these medications, we sought to characterize the association between non-narcotic medications and milligram morphine equivalent (MME) narcotic score during the postoperative inpatient stay.

Methods: We reviewed 260 consecutive ERAS cystectomy patients. The MME impact of non-narcotic compliance and cumulative dose of medication received was evaluated separately with general linear models. We also assessed relationship of non-narcotic compliance to patient reported pain score, length of stay (LOS), and time to return of bowel function (ROBF) and performed manual review of postoperative documentation to identify reasons for medication noncompliance.

Results: Compliance with postoperative acetaminophen, gabapentin, and ketorolac was low. There was an inverse relationship between ketorolac dose and MME on postoperative day 1 (-0.026 MME/mg; P = 0.004) and postoperative day 2 (-0.33 MME/mg; P < 0.001). Compliance with ketorolac was associated with lower MME on postoperative day 1 (26.1 MME v. 33.6 MME; P = 0.023). There were no such associations identified with gabapentin or acetaminophen. Gabapentin compliance was associated with earlier ROBF (3.7 days v. 4.3 days; P = 0.006). Ketorolac compliance was associated with lower pain score on POD1 (3.25 VAS v. 4.07 VAS; P = 0.019) and POD2 (3.05 VAS v. 3.85 VAS; P = 0.040) There was no association between medication compliance and LOS. The most common reasons identified for non-compliance with gabapentin and ketorolac were renal function concerns (38% and 40% respectively), bleeding concerns with ketorolac (20%) and concerns for neurologic adverse effect with gabapentin (16%).

Conclusion: Compliance with non-narcotic medications in our ERAS cystectomy protocol was poor. There was a modest association with ketorolac and postoperative MME but no association with gabapentin or acetaminophen. Further study will clarify the role of these medications for cystectomy patients. Component specific analysis of protocolized care is valuable and may alter care pathways.

Keywords: Analgesia; Cystectomy; ERAS.